What does Femring (estradiol acetate vaginal ring) safety depend on for someone who still has a uterus?
Femring is a vaginal estradiol (estrogen) product. For women with a uterus, using estrogen alone can increase the risk of endometrial (uterine lining) overgrowth and cancer. Standard clinical practice is to add a progestin (a “progestogen”) to help protect the endometrium when estrogen is used in women who have not had a hysterectomy.
Is Femring “safe” if you have a uterus but take a progestin?
The key point for safety is whether endometrial protection is provided. In people with an intact uterus, Femring is generally used in a regimen that includes an appropriate progestin. When estrogen and progestin are used together, the endometrial safety concern is reduced compared with estrogen alone.
What if you use Femring without a progestin when you have a uterus?
Using an estrogen product like Femring without progestin in a person with a uterus can raise the risk of abnormal uterine bleeding and endometrial hyperplasia (thickening) and, over time, may increase the risk of endometrial cancer. This is why many estrogen therapies require combined therapy for patients with a uterus.
What uterine or bleeding symptoms should prompt medical attention?
If you use Femring and develop new or unusual vaginal bleeding—especially bleeding that starts after a period of no bleeding—contact a clinician promptly. New uterine bleeding can be a sign that the endometrium is being affected and may need evaluation.
Practical next step
If you have a uterus and are considering or already using Femring, the safety decision is mainly about whether you are also taking a progestin (and that the regimen is appropriate for your individual risk factors). A clinician can confirm the correct regimen based on your medical history and current medications.
Sources (provided information wasn’t enough to cite Femring-specific labeling here).